Blood clot drug totally ineffective as post-Covid treatment, research finds

A drug to reduce blood clots, widely prescribed to Covid-19 patients after discharge from hospital, does not lessen their chances of readmission or improve survival, according to groundbreaking research which is set to change treatment protocols around the world. The results of the UK-wide trial, led by Addenbrooke’s Hospital and the University of Cambridge, were shared with the Financial Times. They found that prescribing the anticoagulant Apixaban did not help patients recovering from moderate and severe Covid and in a small number of cases caused serious harm.